https://www.thebodypro.com/author/bob-huff

Latest by Bob Huff

Promo Image

World CAB II: Discussing Generic Drug Availability

In January 2005, an unprecedented meeting was held in Mumbai, India, between four manufacturers of affordable generic antiretroviral medicines and 30 advocates for HIV treatment access drawn from every region of the world. This was the second meeting...

Promo Image
Men Who Have Sex With Men

Summaries of Recently Published Research on HIV Risk and Drug Use Among Men Who Have Sex With Men

The Journal of Urban Health recently released an advanced access version of a special issue devoted to investigations of substance use and sexual risk behavior among men who have sex with men (MSM). Some of these papers may offer useful insights for ...

Promo Image
News

One Is the Loneliest Number

A group of HIV/AIDS community doctors and organization leaders gathered in the offices of the New York City Department of Health and Mental Hygiene on a Friday morning in early February 2005. They had been summoned by Commissioner Thomas Frieden to a...

Promo Image

Revisiting Monotherapy: Heresy or Revised Orthodoxy?

After the widespread introduction of triple combination antiretroviral therapy in 1996 caused AIDS deaths to plummet, the earlier practice of single-drug treatment -- or monotherapy -- seemed like an embarrassing phase of medical ignorance. By then, ...

Promo Image
Viewpoints

Change and Rumors of Change

In nearly every corner of the globe, HIV treatment advocates are working for people living with HIV/AIDS, helping them to get the care they need and the respect they deserve; helping them to get the most out of whatever medications are available; to ...

Promo Image

CD4 Monitoring in Resource-Limited Settings: The State of the Art at AIDS 2004

With conventional CD4 T-cell counts and viral load tests all but unaffordable for routine use in resource-poor settings where low-cost antiretroviral medications are now being offered, there has been a disorganized scramble to come up with alternativ...

Promo Image

HIV Coreceptor Drugs on the Horizon

A Canadian company, Anormed Inc., is carving out a specialty niche for itself as a developer of drugs that bind to chemokine receptors, such as CCR5 and CXCR4. They were the first to put an X4 blocking drug into people with HIV and proved that the co...

Promo Image

Salvage Therapy II Think Tank: Proof of Concept Studies/Translational Research; New Hypotheses

A personal take on Panel 2. Discussion leader: Kimberly Struble.

So you've developed a new drug that is designed to block HIV at a novel point in its lifecycle. This is not a "me-too" drug but a whole new approach. Your drug is nicely active again...

Promo Image
News

Abbott's Norvir Price Hike Is Bad Medicine

On May 25, 2004, the NIH heard public statements concerning a petition to invoke the march-in provisions of the Bayh-Dole Act on Abbott Laboratory's Norvir. The law says that patented inventions developed in part with public funds can be reassigned t...

Promo Image
India

Progress on Antiretroviral Access in India: Interview With Khousalya Periaswamy

What is the situation for access to antiretroviral (ARV) drugs in India now?

In April, the government started giving free ARV drugs in six high prevalence states in India, but only a few people are getting them so far. They are focusing on high prev...